ArticleFrontiers in medicine2025
Inequalities and age-period-cohort effects of global and regional burden for interstitial lung disease and pulmonary sarcoidosis: based on Global Burden of Disease study 2021.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Advances in pharmacotherapy for fibrotic interstitial lung disease.Medical review (2021) · 2026Review
- Spain's Sarcoidosis Mortality: An Evolving Public Health Challenge.Open respiratory archivesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Interstitial lung disease (ILD) and pulmonary sarcoidosis pose significant disease burdens on a global scale. Methods: The underlying data was derived from the Global Burden of Disease (GBD) 2021 database. The disease burden was quantified through age-standardized rates (ASRs) and numbers of disability-adjusted life years (DALYs), prevalence, and incidence. The indicators' dynamic trends are captured through Joinpoint analysis and its average annual percentage change (AAPC). Concentration Index (CI) and Slope Index (SI) were employed to characterize the imbalances in the global disease burden. The age-period-cohort model was utilized to elucidate temporal trends in sociobiological factors on the disease burden. Results: Between 1992 and 2021, the ASRs of ILD and pulmonary sarcoidosis have increased globally. For another, the imbalanced distribution of disease burden increased, with more pronounced in high socio-demographic index (SDI) regions. Besides, age-standardized DALY rates (ASDRs) for ILD and pulmonary sarcoidosis were positively associated with age and period effects worldwide and complexly associated with cohort effects, increasing between 1882 and 1928 birthed cohorts and reducing after 1982. However, the distinct period-effect and cohort-effect curves observed in Africa which illustrate a negative correlation trend are noteworthy. Conclusion: Between 1992 and 2021, the global burden of ILD and pulmonary sarcoidosis increased, which were higher in high SDI countries and among the elderly. Furthermore, the disease burden increased with age and period and decreased for those born after 1982. However, the risk ratios of disease in Africa were negative with period-effect and cohort-effects, deserving effective interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.